MTS108
/ METiS TechBio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
A biparatopic DLL3-targeting trispecific T-cell engager delivered by mRNA-LNP drives potent anti-tumor activity in vitroandin vivo
(AACR 2026)
- "Against SHP-77 cells, MTS108 exhibited an EC₅₀ more than 10-fold lower than that of the approved therapeutic Xaluritamig. These data demonstrate that an mRNA-LNP platform can effectively deliver a biparatopic DLL3-targeting trispecific TCE with potent and superior anti-tumor activity and a favorable safety profile. MTS108 represents a promising therapeutic candidate and supports advancement of mRNA-encoded TCEs toward clinical evaluation."
Preclinical • Trispecific • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3
1 to 1
Of
1
Go to page
1